scholarly journals Recent Advances in Desmoid Tumor Therapy

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2135
Author(s):  
Andrea Napolitano ◽  
Alessandro Mazzocca ◽  
Mariella Spalato Ceruso ◽  
Alessandro Minelli ◽  
Francesca Baldo ◽  
...  
Keyword(s):  
Desmoid Tumor ◽  
Low Dose ◽  
Kinase Inhibitors ◽  
Tumor Therapy ◽  
Soft Tissue Sarcomas ◽  
Good Prognosis ◽  
Recent Advances ◽  
The Family ◽  
Proliferative Disease ◽  
Low Dose Chemotherapy

The desmoid tumor is a locally aggressive proliferative disease within the family of soft-tissue sarcomas. Despite its relatively good prognosis, the clinical management of desmoid tumors requires constant multidisciplinary evaluation due to its highly variable clinical behavior. Recently, active surveillance has being regarded as the appropriate strategy at diagnosis, as indolent persistence or spontaneous regressions are not uncommon. Here, we review the most recent advances in desmoid tumor therapy, including low-dose chemotherapy and treatment with tyrosine kinase inhibitors. We also explore the recent improvements in our knowledge of the molecular biology of this disease, which are leading to clinical trials with targeted agents.

Successful Low-Dose Chemotherapy Using Vinblastine and Methotrexate for the Treatment of an Ileoanal Pouch Mesenteric Desmoid Tumor: Report of a Case

2004 ◽  
Vol 47 (2) ◽  
pp. 246-249 ◽  
Author(s):  
Toru Kono ◽  
Ichiro Tomita ◽  
Naoyuki Chisato ◽  
Minoru Matsuda ◽  
Akitoshi Kakisaka ◽  
...  
Keyword(s):  
Desmoid Tumor ◽  
Low Dose ◽  
Ileoanal Pouch ◽  
Low Dose Chemotherapy

Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy

2021 ◽  
Author(s):  
Yin Qianmei ◽  
Su Zehong ◽  
Wang Guang ◽  
Li Hui ◽  
Gaojian Lian
Keyword(s):  
Tumor Immunity ◽  
Tumor Therapy ◽  
Treg Cells ◽  
Recent Advances

scholarly journals Immunomodulatory Effect of Green Tea Treatment in Combination with Low-dose Chemotherapy in Elderly Acute Myeloid Leukemia Patients with Myelodysplasia-related Changes

2021 ◽  
Vol 20 ◽  
pp. 153473542110026
Author(s):  
Andrana K. Calgarotto ◽  
Ana L. Longhini ◽  
Fernando V. Pericole de Souza ◽  
Adriana S. Santos Duarte ◽  
Karla P. Ferro ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Green Tea ◽  
Regulatory T Cell ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
Related Factor ◽  
Low Dose Chemotherapy ◽  
Acute Myeloid

Green tea (GT) treatment was evaluated for its effect on the immune and antineoplastic response of elderly acute myeloid leukemia patients with myelodysplasia-related changes (AML-MRC) who are ineligible for aggressive chemotherapy and bone marrow transplants. The eligible patients enrolled in the study (n = 10) received oral doses of GT extract (1000 mg/day) alone or combined with low-dose cytarabine chemotherapy for at least 6 months and/or until progression. Bone marrow (BM) and peripheral blood (PB) were evaluated monthly. Median survival was increased as compared to the control cohort, though not statistically different. Interestingly, improvements in the immunological profile of patients were found. After 30 days, an activated and cytotoxic phenotype was detected: GT increased total and naïve/effector CD8+ T cells, perforin+/granzyme B+ natural killer cells, monocytes, and classical monocytes with increased reactive oxygen species (ROS) production. A reduction in the immunosuppressive profile was also observed: GT reduced TGF-β and IL-4 expression, and decreased regulatory T cell and CXCR4+ regulatory T cell frequencies. ROS levels and CXCR4 expression were reduced in bone marrow CD34+ cells, as well as nuclear factor erythroid 2–related factor 2 (NRF2) and hypoxia-inducible factor 1α (HIF-1α) expression in biopsies. Immune modulation induced by GT appears to occur, regardless of tumor burden, as soon as 30 days after intake and is maintained for up to 180 days, even in the presence of low-dose chemotherapy. This pilot study highlights that GT extracts are safe and could improve the immune system of elderly AML-MRC patients.

Recent advances in microneedles for tumor therapy and diagnosis

2021 ◽  
Vol 23 ◽  
pp. 101036
Author(s):  
Shiyang Lin ◽  
Yi Cao ◽  
Jiajie Chen ◽  
Zhengfang Tian ◽  
Yufang Zhu
Keyword(s):  
Tumor Therapy ◽  
Recent Advances ◽  
Therapy And Diagnosis

scholarly journals The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3865
Author(s):  
Tânia Fortes-Andrade ◽  
Jani Sofia Almeida ◽  
Luana Madalena Sousa ◽  
Manuel Santos-Rosa ◽  
Paulo Freitas-Tavares ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Nk Cells ◽  
Nk Cell ◽  
Malignant Tumors ◽  
Soft Tissue Sarcomas ◽  
Good Prognosis ◽  
Regulatory Pathways ◽  
Immunological Profile ◽  
Study Support

Soft-tissue sarcomas (STS) represent about 80% of sarcomas, and are a heterogeneous group of rare and malignant tumors. STS arise from mesenchymal tissues and can grow into structures such as adipose tissue, muscles, nervous tissue and blood vessels. Morphological evaluation has been the standard model for the diagnosis of sarcomas, and even in samples with similar characteristics, they present a diversity in cytogenetic and genetic sequence alterations, which further increases the diversity of sarcomas. This variety is one of the main challenges for the classification and understanding of STS patterns, as well as for their respective treatments, which further decreases patient survival (<5 years). Despite some studies, little is known about the immunological profile of STS. As for the immunological profile of STS in relation to NK cells, there is also a shortage of studies. Observations made in solid tumors show that the infiltration of NK cells in tumors is associated with a good prognosis of the disease. Notwithstanding the scarcity of studies to characterize NK cells, their receptors, and ligands in STS, it is noteworthy that the progression of these malignancies is associated with altered NK phenotypes. Despite the scarcity of information on the function of NK cells, their phenotypes and their regulatory pathways in STS, the findings of this study support the additional need to explore NK cell-based immunotherapy in STS further. Some clinical trials, very tentatively, are already underway. STS clinical trials are still the basis for adoptive NK-cell and cytokine-based therapy.

Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors

2017 ◽  
Vol 59 (3) ◽  
pp. 766-769 ◽  
Author(s):  
Emilie Cayssials ◽  
Florence Tartarin ◽  
Joëlle Guilhot ◽  
Nathalie Sorel ◽  
Jean Claude Chomel ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
Kinase Inhibitors ◽  
Molecular Response

Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers

2004 ◽  
Vol 22 (1) ◽  
pp. 27-37 ◽  
Author(s):  
Christopher Guerin ◽  
Alessandro Olivi ◽  
Jon D. Weingart ◽  
H. Christopher Lawson ◽  
Henry Brem
Keyword(s):  
Drug Delivery ◽  
Brain Tumor ◽  
Tumor Therapy ◽  
Recent Advances ◽  
Brain Tumor Therapy
Sign in / Sign up

Export Citation Format

Share Document